行情

ARCT

ARCT

Arcturus
NASDAQ

实时行情|Nasdaq Last Sale

15.19
+1.43
+10.39%
盘后: 15.35 +0.16 +1.05% 16:32 04/09 EDT
开盘
14.00
昨收
13.76
最高
15.33
最低
13.77
成交量
18.10万
成交额
--
52周最高
19.00
52周最低
5.70
市值
2.30亿
市盈率(TTM)
-6.3250
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ARCT价格均价为24.43,最高价位32.00,最低价为18.00。

EPS

ARCT 新闻

更多
  • Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development Intensifies
  • Benzinga · 1天前
  • Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development Intensifies
  • Benzinga · 1天前
  • Biohaven on go with study of vazegepant in COVID-19 as others take action amid the pandemic
  • seekingalpha · 1天前
  • Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
  • GlobeNewswire · 1天前

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

ARCT 简况

Arcturus Therapeutics Holdings Inc. is a ribonucleic acid (RNA) medicines company focused on liver and respiratory diseases. In addition to its internal messenger RNA (mRNA) platform, its lipid nanoparticle deliver system, LUNAR, enables multiple nucleic acid medicines. It is expertized in the discovery and development of RNA medicines, including in the production of RNA drug substance and nanoparticle-formulated drug product. It has a pipeline of seven drugs in the late-stage discovery and early-stage development out of which two are wholly-owned and five are pharma partnered programs. It is focused on applying its technologies to develop RNA medicines in multiple therapeutic approaches, which include mRNA, deoxyribonucleic acid (DNA), and replicon protein replacement for therapeutics and protein delivery for vaccines; small interfering RNA (siRNA), microRNA, and antisense oligonucleotides knockdown of genes overexpressed in disease; and CRISPR, TALEN and zinc finger proteins.
展开

微牛提供Arcturus Therapeutics Ltd(NASDAQ-ARCT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ARCT股票新闻,以帮助您做出投资决策。